257 related articles for article (PubMed ID: 14694918)
21. Clinical pharmacokinetics of morphine and its metabolites during morphine dose titration for chronic cancer pain.
De Gregori S; Minella CE; De Gregori M; Tinelli C; Ranzani GN; Govoni S; Allegri M; Regazzi M
Ther Drug Monit; 2014 Jun; 36(3):335-44. PubMed ID: 24595069
[TBL] [Abstract][Full Text] [Related]
22. Plasma concentrations and renal clearance of morphine, morphine-3-glucuronide and morphine-6-glucuronide in cancer patients receiving morphine.
Somogyi AA; Nation RL; Olweny C; Tsirgiotis P; van Crugten J; Milne RW; Cleary JF; Danz C; Bochner F
Clin Pharmacokinet; 1993 May; 24(5):413-20. PubMed ID: 8504624
[TBL] [Abstract][Full Text] [Related]
23. Oral morphine in cancer pain: influences on morphine and metabolite concentration.
McQuay HJ; Carroll D; Faura CC; Gavaghan DJ; Hand CW; Moore RA
Clin Pharmacol Ther; 1990 Sep; 48(3):236-44. PubMed ID: 2401122
[TBL] [Abstract][Full Text] [Related]
24. The intravenous to oral relative milligram potency ratio of morphine during chronic dosing in cancer pain.
Lasheen W; Walsh D; Mahmoud F; Sarhill N; Rivera N; Davis M; Lagman R; Legrand S
Palliat Med; 2010 Jan; 24(1):9-16. PubMed ID: 19910396
[TBL] [Abstract][Full Text] [Related]
25. The bioavailability and pharmacokinetics of subcutaneous, nebulized and oral morphine-6-glucuronide.
Penson RT; Joel SP; Roberts M; Gloyne A; Beckwith S; Slevin ML
Br J Clin Pharmacol; 2002 Apr; 53(4):347-54. PubMed ID: 11966664
[TBL] [Abstract][Full Text] [Related]
26. Plasma morphine and glucuronide (M3G and M6G) concentrations in hospice inpatients.
Ashby M; Fleming B; Wood M; Somogyi A
J Pain Symptom Manage; 1997 Sep; 14(3):157-67. PubMed ID: 9291702
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological consequences of long-term morphine treatment in patients with cancer and chronic non-malignant pain.
Andersen G; Sjøgren P; Hansen SH; Jensen NH; Christrup L
Eur J Pain; 2004 Jun; 8(3):263-71. PubMed ID: 15109977
[TBL] [Abstract][Full Text] [Related]
28. Morphine analgesia in cancer pain: role of the glucuronides.
Penson RT; Joel SP; Gloyne A; Clark S; Slevin ML
J Opioid Manag; 2005; 1(2):83-90. PubMed ID: 17319252
[TBL] [Abstract][Full Text] [Related]
29. Lack of morphine-6-glucuronide antinociception after morphine treatment. Is morphine-3-glucuronide involved?
Faura CC; Olaso JM; Cabanes CG; Horga JF
Pain; 1996 Apr; 65(1):25-30. PubMed ID: 8826486
[TBL] [Abstract][Full Text] [Related]
30. Opioid rotation from oral morphine to oral oxycodone in cancer patients with intolerable adverse effects: an open-label trial.
Narabayashi M; Saijo Y; Takenoshita S; Chida M; Shimoyama N; Miura T; Tani K; Nishimura K; Onozawa Y; Hosokawa T; Kamoto T; Tsushima T;
Jpn J Clin Oncol; 2008 Apr; 38(4):296-304. PubMed ID: 18326541
[TBL] [Abstract][Full Text] [Related]
31. Concentrations of morphine, morphine-6-glucuronide and morphine-3-glucuronide in serum and cerebrospinal fluid following morphine administration to patients with morphine-resistant pain.
Goucke RC; Hackett PL; Ilett KF
Pain; 1994 Feb; 56(2):145-149. PubMed ID: 8008404
[TBL] [Abstract][Full Text] [Related]
32. The bioavailability of morphine applied topically to cutaneous ulcers.
Ribeiro MD; Joel SP; Zeppetella G
J Pain Symptom Manage; 2004 May; 27(5):434-9. PubMed ID: 15120772
[TBL] [Abstract][Full Text] [Related]
33. HPLC determination of morphine, morphine-3-glucuronide and morphine-6-glucuronide in human serum of oncological patients after administration of morphine drugs.
Netriova J; Blahova E; Johanesova Z; Brandsteterova E; Lehotay J; Serdt K; Mocak J
Pharmazie; 2006 Jun; 61(6):528-34. PubMed ID: 16830402
[TBL] [Abstract][Full Text] [Related]
34. Developmental pharmacokinetics of morphine and its metabolites in neonates, infants and young children.
Bouwmeester NJ; Anderson BJ; Tibboel D; Holford NH
Br J Anaesth; 2004 Feb; 92(2):208-17. PubMed ID: 14722170
[TBL] [Abstract][Full Text] [Related]
35. Parenteral morphine prescribing patterns among inpatients with pain from advanced cancer: a prospective survey of intravenous and subcutaneous use.
Walsh D; Perin ML; McIver B
Am J Hosp Palliat Care; 2006; 23(5):353-9. PubMed ID: 17060302
[TBL] [Abstract][Full Text] [Related]
36. Morphine, morphine-6-glucuronide and morphine-3-glucuronide pharmacokinetics in newborn infants receiving diamorphine infusions.
Barrett DA; Barker DP; Rutter N; Pawula M; Shaw PN
Br J Clin Pharmacol; 1996 Jun; 41(6):531-7. PubMed ID: 8799518
[TBL] [Abstract][Full Text] [Related]
37. Plasma morphine-3-glucuronide, morphine-6-glucuronide and morphine concentrations in patients receiving long-term epidural morphine.
Schneider JJ; Ravenscroft PJ; Cavenagh JD; Brown AM; Bradley JP
Br J Clin Pharmacol; 1992 Nov; 34(5):431-3. PubMed ID: 1467139
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries.
Perreault S; Choinière M; du Souich PB; Bellavance F; Beauregard G
Ann Pharmacother; 2001 Dec; 35(12):1588-92. PubMed ID: 11793627
[TBL] [Abstract][Full Text] [Related]
39. Plasma levels of morphine and morphine glucuronides in the treatment of cancer pain: relationship to renal function and route of administration.
Peterson GM; Randall CT; Paterson J
Eur J Clin Pharmacol; 1990; 38(2):121-4. PubMed ID: 2338107
[TBL] [Abstract][Full Text] [Related]
40. Relationships between plasma concentrations of morphine, morphine-3-glucuronide, morphine-6-glucuronide, and intravenous morphine titration outcomes in the postoperative period.
Hammoud HA; Aymard G; Lechat P; Boccheciampe N; Riou B; Aubrun F
Fundam Clin Pharmacol; 2011 Aug; 25(4):518-27. PubMed ID: 20825489
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
